BNP Paribas Asset Management’s Ligand Pharmaceuticals LGND Stock Holding History
Bought
Maintained
Sold
Other funds holding LGND
JT
CAM
BNP Paribas Asset Management's LGND Position: Q2 2026 in Review
BNP Paribas Asset Management increased its Ligand Pharmaceuticals (LGND) stake by 225% in Q2 2026, buying an estimated $170K and bringing the position to 1,044 shares worth $330K. The position accounts for ﹤0.01% of the portfolio, ranked #1347.
BNP Paribas Asset Management first reported a position in LGND in Q2 2025 and has held it in 5 quarters since. 417 funds tracked by Wall St. Rank hold LGND as of Q2 2026.
- BNP Paribas Asset Management held 1,044 shares of Ligand Pharmaceuticals worth $330K as of Q2 2026.
- BNP Paribas Asset Management bought 723 Ligand Pharmaceuticals shares in Q2 2026, an estimated $170K.
- Ligand Pharmaceuticals made up ﹤0.01% of BNP Paribas Asset Management's portfolio in Q2 2026, its #1347 holding.
- BNP Paribas Asset Management first reported a position in Ligand Pharmaceuticals in Q2 2025 and has held it in 5 quarters since.
- 417 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q2 2026.
Based on BNP Paribas Asset Management's 13F filing for Q2 2026, filed 13 Aug 2026.